# PSUNRISE - Prospective Study Using Remicade in Psoriasis Patients With an Inadequate Response to Etanercept

> **NCT00527072** · PHASE3 · COMPLETED · sponsor: **Centocor Ortho Biotech Services, L.L.C.** · enrollment: 217 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **BIOLOGICAL:** infliximab

## Key facts

- **NCT ID:** NCT00527072
- **Lead sponsor:** Centocor Ortho Biotech Services, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2009-05
- **Final completion:** 2009-10
- **Target enrollment:** 217 (ACTUAL)
- **Last updated:** 2012-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00527072

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00527072, "PSUNRISE - Prospective Study Using Remicade in Psoriasis Patients With an Inadequate Response to Etanercept". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00527072. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*